EntryPoint Capital LLC Takes $306,000 Position in Grail, Inc. (NASDAQ:GRAL)

EntryPoint Capital LLC acquired a new position in Grail, Inc. (NASDAQ:GRAL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 17,153 shares of the company's stock, valued at approximately $306,000. EntryPoint Capital LLC owned approximately 0.05% of Grail as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Crcm LP bought a new stake in shares of Grail during the 4th quarter worth $65,061,000. Primecap Management Co. CA purchased a new stake in Grail during the fourth quarter worth about $37,118,000. Vanguard Group Inc. bought a new stake in Grail in the fourth quarter worth about $25,902,000. Bank of New York Mellon Corp purchased a new position in Grail in the fourth quarter valued at about $6,262,000. Finally, TCW Group Inc. bought a new position in shares of Grail during the 4th quarter valued at approximately $5,095,000.

Insider Buying and Selling at Grail

In other Grail news, CFO Aaron Freidin sold 1,816 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $56,659.20. Following the completion of the transaction, the chief financial officer now owns 335,170 shares in the company, valued at $10,457,304. This trade represents a 0.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert P. Ragusa sold 7,625 shares of Grail stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.21, for a total value of $237,976.25. Following the transaction, the chief executive officer now directly owns 828,662 shares of the company's stock, valued at $25,862,541.02. The trade was a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,550 shares of company stock valued at $360,436 in the last 90 days.

Remove Ads

Analyst Ratings Changes

Separately, Morgan Stanley lifted their price target on shares of Grail from $16.00 to $20.00 and gave the stock an "equal weight" rating in a report on Tuesday, March 18th.

Grail Trading Down 1.7 %

GRAL traded down $0.44 during trading hours on Tuesday, hitting $25.10. The stock had a trading volume of 804,439 shares, compared to its average volume of 1,218,058. Grail, Inc. has a 1 year low of $12.33 and a 1 year high of $63.99. The company's fifty day simple moving average is $34.32 and its 200 day simple moving average is $22.64.

Grail (NASDAQ:GRAL - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.41) by $2.55. The business had revenue of $38.25 million during the quarter, compared to the consensus estimate of $35.33 million. As a group, research analysts forecast that Grail, Inc. will post -15.15 EPS for the current year.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.